Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors

被引：18
作者：
Ghosh, Arun K. [1 ,2 ]
Chapsal, Bruno D. [1 ,2 ]
Steffey, Melinda [1 ,2 ]
Agniswamy, Johnson [3 ]
Wang, Yuan-Fang [3 ]
Amano, Masayuki [4 ,5 ]
Weber, Irene T. [3 ]
Mitsuya, Hiroaki [4 ,5 ,6 ]
机构：
[1] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[2] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
[3] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA
[4] Kumamoto Univ, Dept Hematol, Grad Sch Med & Pharmaceut Sci, Kumamoto 8608556, Japan
[5] Kumamoto Univ, Dept Infect Dis, Grad Sch Med & Pharmaceut Sci, Kumamoto 8608556, Japan
[6] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 06期
基金：
美国国家卫生研究院;
关键词：
HIV-1 protease inhibitors; P2; ligand; Drug resistance; Design and synthesis; X-ray crystal structure; DRUG-RESISTANT MUTANTS; BIOLOGICAL EVALUATION; P2-LIGANDS; BACKBONE;
D O I：
10.1016/j.bmcl.2012.01.061
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The design, synthesis, and biological evaluation of novel C3-substituted cyclopentyltetrahydrofuranyl (Cp-THF)-derived HIV-1 protease inhibitors are described. Various C3-functional groups on the Cp-THF ligand were investigated in order to maximize the ligand-binding site interactions in the flap region of the protease. Inhibitors 3c and 3d have displayed the most potent enzyme inhibitory and antiviral activity. Both inhibitors have maintained impressive activity against a panel of multidrug resistant HIV-1 variants. A high-resolution X-ray crystal structure of 3c-bound HIV-1 protease revealed a number of important molecular insights into the ligand-binding site interactions. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2308 / 2311
页数：4
相关论文
共 50 条
  • [41] HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2′ Ligands To Optimize Hydrogen Bonding in the Substrate Envelope
    Rusere, Linah N.
    Lockbaum, Gordon J.
    Lee, Sook-Kyung
    Henes, Mina
    Kosovrasti, Klajdi
    Spielvogel, Ean
    Nalivaika, Ellen A.
    Swanstrom, Ronald
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    Ali, Akbar
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 8062 - 8079
  • [42] Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants
    Ghosh, Arun K.
    Rao, Kalapala Venkateswara
    Nyalapatla, Prasanth R.
    Kovela, Satish
    Brindisi, Margherita
    Osswald, Heather L.
    Reddy, Bhavanam Sekhara
    Agniswamy, Johnson
    Wang, Yuan-Fang
    Aoki, Manabu
    Hattori, Shin-ichiro
    Weber, Irene T.
    Mitsuya, Hiroaki
    CHEMMEDCHEM, 2018, 13 (08) : 803 - 815
  • [43] Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies
    Ghosh, Arun K.
    Brindisi, Margherita
    Yen, Yu-Chen
    Lendy, Emma K.
    Kovela, Satish
    Cardenas, Emilio Leal
    Reddy, Bhavanam Sekhara
    Rao, Kalapala Venketeswara
    Downs, Deborah
    Huang, Xiangping
    Tang, Jordan
    Mesecar, Andrew D.
    CHEMMEDCHEM, 2019, 14 (05) : 545 - 560
  • [44] Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands
    Ghosh, Arun K.
    Gemma, Sandra
    Simoni, Elena
    Baldridge, Abigail
    Walters, D. Eric
    Ide, Kazuhiko
    Tojo, Yasushi
    Koh, Yasuhiro
    Amano, Masayuki
    Mitsuya, Hiroaki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (03) : 1241 - 1246
  • [45] Docking and 3-D QSAR studies on the binding of tetrahydropyrimid-2-one HIV-1 protease inhibitors
    Rao, Shashidhar N.
    Balaji, Govardhan A.
    Balaji, Vitukudi N.
    JOURNAL OF MOLECULAR STRUCTURE, 2013, 1042 : 86 - 103
  • [46] HIV-1 protease inhibitors with a tertiary alcohol containing transition-state mimic and various P2 and P1′ substituents
    Ohrngren, Per
    Wu, Xiongyu
    Persson, Magnus
    Ekegren, Jenny K.
    Wallberg, Hans
    Vrang, Lotta
    Rosenquist, Asa
    Samuelsson, Bertil
    Unge, Torsten
    Larhed, Mats
    MEDCHEMCOMM, 2011, 2 (08) : 701 - 709
  • [47] Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1′ ligand to enhance binding with S1′ subsite
    Zhu, Mei
    Ma, Ling
    Dong, Biao
    Zhang, Guoning
    Wang, Juxian
    Zhou, Jinming
    Cen, Shan
    Wang, Yucheng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (16) : 115623
  • [48] Design, synthesis, and X-ray structural studies of a series of highly potent selective, and drug-like G protein-coupled receptor kinase 5 inhibitors
    Ghosh, Arun K.
    Chen, Yueyi
    Gadi, Ranjith Kumar
    Sonawane, Amol
    Gamage, Sandali Piladuwa
    Tesmer, John J. G.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 282
  • [49] Novel wild type and mutate HIV-1 protease inhibitors containing heteroaryl carboxamides in P2: Synthesis, biological evaluations and in silico ADME prediction
    Armentano, Maria Francesca
    Lupattelli, Paolo
    Bisaccia, Faustino
    D'Orsi, Rosarita
    Miglionico, Rocchina
    Nigro, Ilaria
    Santarsiere, Alessandro
    Berti, Federico
    Funicello, Maria
    Chiummiento, Lucia
    RESULTS IN CHEMISTRY, 2023, 6
  • [50] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants
    Zhu, Mei
    Dou, Yue
    Ma, Ling
    Dong, Biao
    Zhang, Fan
    Zhang, Guoning
    Wang, Juxian
    Zhou, Jinming
    Cen, Shan
    Wang, Yucheng
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (06): : 1196 - 1204
12345